Rachel E Dew

Associate Professor of Psychiatry and Behavioral Sciences

Psychiatry, Child & Family Mental Health & Community Psychiatry

Box 3527, Durham, NC 27710

2608 Erwin Road Lakeview Pavi, Durham, NC 27705

More About This Person

At a Glance

Credentials
1. Education

Academic Experience
1. Current Appointments & Affiliations
2. Previous Appointments & Affiliations

Expertise

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition
1. In the News

Professional Activities

Selected Grants

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 for the Treatment of Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD).

Clinical TrialPrincipal Investigator · Awarded by Supernus Pharmaceuticals, Inc. · 2024 - 2027

A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 years old) with Attention-Deficit/Hyperactivity Disorder (ADHD)

Clinical TrialPrincipal Investigator · Awarded by Supernus Pharmaceuticals, Inc. · 2024 - 2026

NC PAL Expansion

Public ServicePhysician · Awarded by NC DHHS · 2022 - 2026

Longitudinal Analysis of ADHD Medication use, Functional Outcomes, and Health Equity in Children with ADHD

ResearchCollaborator · Awarded by Southern Nursing Research Society · 2025 - 2026

Limbix Spark: a CBT-based mobile intervention for adolescent depression (NIH FUNDING)

ResearchCo Investigator · Awarded by Limbix · 2021 - 2023

Real-World Evidence of Duration of Effect of Adhansia XR for Treatment of ADHD (RE-DAX)

Clinical TrialPrincipal Investigator · Awarded by Adlon Therapeutics · 2020 - 2022

Paternal Transgenerational Epigenetic Legacy from Use of Cannabis

ResearchCollaborator · Awarded by John Templeton Foundation · 2017 - 2022

An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults with Attention-Deficit/Hyperactivity Disorder

Clinical TrialPrincipal Investigator · Awarded by Otsuka America Pharmaceutical · 2019 - 2021

A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults w/ADHD

Clinical TrialPrincipal Investigator · Awarded by Otsuka American Pharmaceutical, Inc · 2018 - 2021

Environment Cue-Reactivity: Brain, Behavior and Clinical Outcomes in Tobacco Use

ResearchPhysician · Awarded by National Institutes of Health · 2014 - 2020

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELGROUP, ADULT LABORATORY CLASSROOM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PRC-063 COMPARED TO PLACEBO IN ADULTS WITH ADHD

Clinical TrialPrincipal Investigator · Awarded by Purdue Pharma · 2018 - 2020

KP415.E01: "A Multicenter, Dose-optimized, double-blind, randomized, placebo-controlled, parallel efficacy laboratory classroom study with KP415 in children with attention-deficit/hyperactivity disorder"

Clinical TrialPrincipal Investigator · Awarded by KemPharm, Inc · 2017 - 2019

Neurobehavioral substrates of propranolol's effects on drug cue reactivity

ResearchCo Investigator · Awarded by National Institutes of Health · 2017 - 2019

A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed with Attention-deficit/Hyperactivity Disorder

Clinical TrialPhysician · Awarded by Shire Pharmaceutical Development US Inc. · 2015 - 2019

A phase 4, double-blind, randomized, parallel group, placebo-controlled study of the efficacy and safety of Quillichew Extended Release chewable tablets (methylphenidate HCl extended release chewable tablets ERCT) in 4-5 year old chldren with ADHD

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2018 - 2019

A Phase 4, 6-Month Open-Label Extension Study to Evaluate the Safety, Tolerability, and Efficacy of Quillichew (Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablets (ERCT) in Children with Attention Deficit Hyperactivity Disorder

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2018 - 2019

Behavioral and genetic mechanisms of smoking risk in individuals with ADHD

ResearchPhysician · Awarded by National Institutes of Health · 2012 - 2018

A Pharmacokinetic Study of Aptensio XR¿ (Methylphenidate Hydrochloride) Extended-Release capsules in Male or Female Pre-School Children 4 to Under 6 years of age with ADHD in Fed Condition

Clinical TrialPhysician · Awarded by Rhodes Pharmaceuticals L.P. · 2015 - 2018

A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention Deficit/Hyperactivity Disorder

Clinical TrialPhysician · Awarded by Shire Pharmaceutical Development US Inc. · 2015 - 2017

A 6-week, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Efficacy and Safety Study of Dasotraline versus Placebo in Subjects 6 to 12 Years of Age with Attention Deficit Hyperactivity Disorder (ADHD)

Clinical TrialPhysician · Awarded by Sunovion Pharmaceuticals, Inc · 2015 - 2017

A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD)

Clinical TrialPhysician · Awarded by Sunovion Pharmaceuticals, Inc · 2015 - 2017

A Ph. 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & ER Formulation (DELEXIS) of Methylphenidate Hydrochloride, on Post waking, Early Mor

Clinical TrialPhysician · Awarded by Ironshore Pharmaceuticals & Development, Inc · 2015 - 2016

An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

Clinical TrialPhysician · Awarded by Sunovion Pharmaceuticals, Inc · 2015 - 2016

SEP-225289 in Adults with Attention Deficit Hyperactivity Disorder (ADHD)

Clinical TrialPhysician · Awarded by Sunovion Pharmaceuticals, Inc · 2014 - 2016

A Phase IIb, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)

Clinical TrialPhysician · Awarded by Neurovance · 2015 - 2016

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Single Oral Doses of SEP-225289 in Subjects 6 to 17 Years of Age with Attention Deficit Hyperactivity Disorder

Clinical TrialPhysician · Awarded by Sunovion Pharmaceuticals, Inc · 2015 - 2015

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADOLESCENT ADHD PATIENTS

Clinical TrialPhysician · Awarded by Purdue Pharma L.P. · 2014 - 2015

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADULT ADHD PATIENTS

Clinical TrialPhysician · Awarded by Purdue Pharma L.P. · 2014 - 2015

A SIX-MONTH, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF PRC-063 IN ADULTS AND ADOLESCENTS WITH ADHD

Clinical TrialPhysician · Awarded by Purdue Pharma L.P. · 2014 - 2015

A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects with Attention-Deficit Hyperactivity Disorder (CEES ADHD)

Clinical TrialPhysician · Awarded by Ironshore Pharmaceuticals & Development, Inc · 2014 - 2015

A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD)

Clinical TrialPhysician · Awarded by Alcobra Ltd. · 2014 - 2015

Amphetamine Extended-Release Oral Suspension in the Treatment of Children with ADHD: A Laboratory School Study

Clinical TrialPhysician · Awarded by Tris Pharma, Inc. · 2014 - 2015

Neuropharmacology of Response Inhibition in Comorbid ADHD and Nicotine Dependence

ResearchPhysician · Awarded by National Institutes of Health · 2009 - 2014

Neural Substrates of Extinction-Based Treatment for Nicotine Dependence

ResearchPhysician · Awarded by National Institutes of Health · 2008 - 2014

Smoking reinforcement in adults with and without ADHD

ResearchPhysician · Awarded by National Institutes of Health · 2009 - 2012